Global Custom Market Research Reports Provider Company

phone

Critical Limb Ischemia - Pipeline Review, H1 2018

  • Published Date: 06 Mar 2018
  • Number of Pages: 132
  • Category: Pharmaceuticals
  • Country: Global
Critical Limb Ischemia - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2018, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 17, 2, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct
Introduction
Global Markets Direct Report Coverage
Critical Limb Ischemia - Overview
Critical Limb Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Critical Limb Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Critical Limb Ischemia - Companies Involved in Therapeutics Development
AnGes MG Inc
apceth Biopharma GmbH
Athersys Inc
BiogenCell Ltd
Caladrius Biosciences Inc
Cynata Therapeutics Ltd
Hemostemix Inc
Histocell SL
ID Pharma Co Ltd
Integene International Holdings LLC
Juventas Therapeutics Inc
Kang Stem Biotech Co Ltd
Kasiak Research Pvt Ltd
Neurofx Inc
Nissan Chemical Industries Ltd
Pharmicell Co Ltd
Pluristem Therapeutics Inc
ReNeuron Group Plc
Rexgenero Ltd
Symic Biomedical Inc
TaiGen Biotechnology Co Ltd
TikoMed AB
U.S. Stem Cell Inc
VESSL Therapeutics Ltd
ViroMed Co Ltd
YiChang Humanwell Pharmaceutical Co Ltd
Critical Limb Ischemia - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AdipoCell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alecmestencel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASCT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
burixafor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-CLI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HC-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NFx-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-104 NP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05285401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Procell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Refacell-CLI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rejuveinix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReN-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cardiovacular Diseases and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Critical Limb Ischemia - Dormant Projects
Critical Limb Ischemia - Discontinued Products
Critical Limb Ischemia - Product Development Milestones
Featured News & Press Releases
Jan 30, 2018: EMA grants Rexgeneros lead product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data
Jan 25, 2018: Rexgenero treats first patient in its Phase III programme with lead product REX-001, a novel cell therapy for the treatment of Critical Limb Ischemia (CLI)
Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
Jan 09, 2018: FDA Clears Pluristems Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study
Dec 20, 2017: Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials
Dec 12, 2017: Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israels Ministry of Health, Supporting Pivotal-Stage Studies
Oct 09, 2017: BioTech Identifies and Files Patent on ProCell Mechanism of Action in Saving Limbs from Amputation
Oct 02, 2017: $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristems PLX-PAD Cells
Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology
Sep 26, 2017: Hemostemix Announces Agreement with CRO Service Provider Topstone Research
Sep 18, 2017: U.S. FDA Grants Fast Track Designation to Pluristems PLX-PAD for the Treatment of Critical Limb Ischemia
Sep 07, 2017: Caladrius Biosciences to Participate at Upcoming September Conferences
Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
Jul 10, 2017: Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017
Jan 23, 2017: Consortium including TrakCel awarded 1.4 million from Innovate UK for commercialisation of Rexgenero cell therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Critical Limb Ischemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Critical Limb Ischemia - Pipeline by AnGes MG Inc, H1 2018
Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H1 2018
Critical Limb Ischemia - Pipeline by Athersys Inc, H1 2018
Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H1 2018
Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Hemostemix Inc, H1 2018
Critical Limb Ischemia - Pipeline by Histocell SL, H1 2018
Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H1 2018
Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, H1 2018
Critical Limb Ischemia - Pipeline by Kang Stem Biotech Co Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Kasiak Research Pvt Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Neurofx Inc, H1 2018
Critical Limb Ischemia - Pipeline by Nissan Chemical Industries Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Pharmicell Co Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc, H1 2018
Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H1 2018
Critical Limb Ischemia - Pipeline by Rexgenero Ltd, H1 2018
Critical Limb Ischemia - Pipeline by Symic Biomedical Inc, H1 2018
Critical Limb Ischemia - Pipeline by TaiGen Biotechnology Co Ltd, H1 2018
Critical Limb Ischemia - Pipeline by TikoMed AB, H1 2018
Critical Limb Ischemia - Pipeline by U.S. Stem Cell Inc, H1 2018
Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H1 2018
Critical Limb Ischemia - Pipeline by ViroMed Co Ltd, H1 2018
Critical Limb Ischemia - Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H1 2018
Critical Limb Ischemia - Dormant Projects, H1 2018
Critical Limb Ischemia - Dormant Projects, H1 2018 (Contd..1), H1 2018
Critical Limb Ischemia - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Critical Limb Ischemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Report Critical Infrastructure Protection-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Critical Infrastructure Protection industry, standing on the readers perspective, delivering detailed market data and

View Report

Report Critical Infrastructure Protection-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Critical Infrastructure Protection industry, standing on the readers perspective, delivering detailed market data and penetrating

View Report

Report Critical Infrastructure Protection-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Critical Infrastructure Protection industry, standing on the readers perspective, delivering detailed market data and penetrating

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports